Health New Drugs Extend Lives Of Men With Resistant Form Of Prostate Cancer

02:30  12 february  2018
02:30  12 february  2018 Source:   gizmodo.com.au

Two Bacteria Revealed as Culprits Behind Colon Cancer in New Study

  Two Bacteria Revealed as Culprits Behind Colon Cancer in New Study The microbes work in disturbing concert to trigger tumor growth.The finding, which surprised the researchers, could eventually lead to new avenues for treatment.

Research has shown that anywhere from two to eight percent of men with prostate cancer worldwide have this particularly hardy form , known as nonmetastatic castration- resistant prostate How Much Is Too Much For a Life -Saving Drug ? Cancer Is Killing Fewer Americans, But a Racial Gap Endures.

New Drugs Extend Lives Of Men With Resistant Form Of Prostate Cancer As a general rule, cancer patients have to worry about the possibility that their

a close up of a sign© Provided by Business Insider Australia

As a general rule, cancer patients have to worry about the possibility that their cancer will return with a vengeance, no matter how successful their initial treatment course may have been. But some men with prostate cancer are left in an even more nerve-wracking state of uncertainty. Their cancer appears practically frozen, not spreading elsewhere but also not responding any further to treatment. Sadly, some patients in this state will eventually develop a full-blown, incurable, and ultimately fatal cancer.

But newresearch, presented this week at the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium held in San Francisco, seems to offer something meaningful to these patients: More time on the clock.

Parkinson's disease symptoms improve with singing, study finds

  Parkinson's disease symptoms improve with singing, study finds They say laughter is the best medicine, but singing is just as good, according to a group of people with Parkinson's disease who took part in an Australian first trial. More than 70 patients from Queensland participated in the ground-breaking Griffith University study that looked at how song could help battle the disease.

In particular, people given the experimental drug apalutamide lived a median length of 40 months before their cancers became metastatic or they died, which It's estimated that three million men in the US currently have prostate cancer , while there are some 160,000 new cases diagnosed annually.

As a general rule, cancer patients have to worry about the possibility that their cancer will return with a vengeance, no matter how successful their initial treatment course may have been. But some men with prostate cancer are left in an even more nerve-wracking state of uncertainty.

Two independent teams of researchers tested out their respective drugs on patients whose stalled prostate cancers seemed to be on the verge of erupting and becoming metastatic, based on their rising levels of prostate-specific antigen, an enzyme used to diagnose and track prostate cancer.

The patients were previously given other standard treatments and were still on hormone therapy that depleted their levels of testosterone -- a form of chemical castration -- since testosterone is known to fuel prostate cancer growth. The trials each randomised its volunteers to either receive the drug or a placebo, and collectively involved around 2600 patients across the globe.

In both trials, those who took the drug survived much longer than those on the placebo. In particular, people given the experimental drug apalutamide lived a median length of 40 months before their cancers became metastatic or they died, which was two years longer than the placebo group. Patients who took enzalutamide similarly lived a median length of 36 months without metastatic cancer, compared to just 14 months for those on placebo.

Hepatitis C drugs not being accessed by thousands of Australians with the disease

  Hepatitis C drugs not being accessed by thousands of Australians with the disease Hundreds of thousands of Australians with hepatitis C are failing to access new curative drugs, despite the Government subsidising them.The trend means the Government is at risk of missing its target to eradicate hepatitis C and of spending far more than necessary on the treatments.

Championing Decentralized Human Rights hu-manity.co. Patient reporting tool from CancerAid now integrates with Epic Systems and Apple HealthKit. Why thousands of AI researchers are boycotting the new Nature journal -The Guardian.

Researchers are looking at newer forms of treatment for early-stage prostate cancer . This drug is already used to treat some other cancers , and is now being tested in men with advanced prostate cancer .

For both drugs, the researchers estimated they had reduced the risk of patients developing metastatic cancer by around 70 per cent. Those on either drug experienced relatively mild side-effects like fainting, fatigue, and hypertension, but patients overall rated their quality of life as highly as they did prior to starting the treatments.

The findings of the apalutamide trial were also published in the New England Journal of Medicine, while the enzalutamide results have yet to be peer-reviewed.

Should all older Australians be taking heart drugs?

  Should all older Australians be taking heart drugs? A world-first study is uncovering the benefits of a popular heart drug that could be helpful, even for healthy older people. Statins are most commonly used to lower cholesterol but scientists believe they could help us live longer and prevent major diseases.One-third of Australians are prescribed statins to prevent heart attack and stroke but researchers believe there could be even bigger benefits. “We’re moving into an area where it’s not just heart attack or stroke.

Prostate cancer , especially low-grade forms found in elderly men , often grows so slowly Insufficient information is available to determine whether seed radiation extends life more readily than the In such men , diagnosing prostate cancer is overdiagnosis—the needless identification of a technically

Fifteen years ago, Michael Jung was already an eminent scientist when his wife asked him a question that would change his career, and extend the lives of many men with a particularly lethal form of prostate cancer . New medication treats drug - resistant prostate cancer in the laboratory.

"It's controlled my cancer," 72-year-old Ron Scolamiero, a Massachusetts patient taking apalutamide since 2012, when he was enrolled in an earlier trial, toldThe New York Times. "I'm so grateful."

Both drugs block the receptors that allow prostate cells to take in testosterone, essentially boosting the effects of the chemical castration. While apalutamide is in development and intended to be the newest generation of these drugs, enzalutamide is already used to treat prostate cancer that has metastasized.

It's estimated that three million men in the US currently have prostate cancer, while there are some 160,000 new cases diagnosed annually. Research has shown that anywhere from two to eight per cent of men with prostate cancer worldwide have this particularly hardy form, known as nonmetastatic castration-resistant prostate cancer.

Human trials of these androgen receptor inhibitors have been ongoing for years, but these are the largest seen yet, both being Phase 3 trials that are needed to win final drug approval from agencies like the U.S. Food and Drug Administration (FDA). The makers of apalutamide, Johnson and Johnson, have already applied for FDA approval, while enzalutamide's makers, Pfizer and Astellas Pharma, are petitioning the FDA to expand its use, according to The Times.

Ovarian cancer may be passed down through dad's X chromosome

  Ovarian cancer may be passed down through dad's X chromosome If your grandmother on your dad's side of the family had ovarian cancer, you and your sisters may have a greater risk of developing the condition.Data from a large, long-term study of US families indicates women may inherit ovarian cancer through the X chromosome passed down from their dad, independently of genes on other chromosomes already associated with the aggressive condition.

Castrate- resistant and hormone-refractory prostate cancer . Hormone-refractory prostate cancer (HRPC) is cancer that is no longer helped by any form of hormone therapy. These drugs can reduce pain and even slow cancer growth in many men .

Read more in “Treatments for metastatic castration- resistant prostate cancer ” above. Bone-modifying drugs . Bone health is an important aspect in the life of men with prostate cancer .

Given the success of these trials, it's likely that other, possibly older and hopefully cheaper drugs of this class will be tested for these patients in the near-future.

Pictures: 20 symptoms that mean you should see your doctor

20 symptoms that mean you should see your doctor: <p>We all have our aches and <strong>pains</strong>, and we all have accidents from time to time. Many of our problems can be dealt with at home and the general rule of thumb is, when in doubt, have it checked out. But what <a href=symptoms or health problems are generally a sign that you should see your doctor or go to an emergency room? Here are 20 of the most common reasons to see your doctor.

" src="/upload/images/real/2018/02/12/20-symptoms-that-mean-you-should-see-your-doctor-p-we-all-have-our-aches-and-strong-pains-strong-and_597668_.jpg?content=1" />
20 symptoms that mean you should see your doctor

Breakthrough treatment for enlarged prostate arrives in Australia .
Nearly half of all men aged over 50 suffer urinary problems caused by an enlarged prostate and as they get older, that statistic continues to rise. While many suffer in silence, even those who do seek medical advice to manage the problem often refuse conventional treatment because most medications and surgical options can result in unwanted side-effects, like sexual dysfunction.But a new procedure with little to no side-effects, known as ‘Rezum’, is now being offered in Australia.

—   Share news in the SOC. Networks

Topical videos:

This is interesting!